Robert Crisci was appointed Director of Legence Corp., effective August 18, 2026. As of November 6, 2026, Legence Corp. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 11, 2026 to August 18, 2026, naming 2 appointments (Form 8-K, August 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Legence Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Legence Corp. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-11 to 2026-08-18. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Legence Corp. files it.
Also on the record for Legence Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G/A, by BCP 8/BEP 3 Holdings Manager L.L.C. | 46.9% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.6% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 4.4% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13G/A, by BCP 8/BEP 3 Holdings Manager L.L.C. | 61.1% of the class | 5%+ stakes | Source |
| April 8, 2026 | IPO filing, Form 424B4 | — | IPO filings | Source |
| April 6, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 2, 2026 | Form D, private offering | $7.25M sold | Form D page | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by BCP 8/BEP 3 Holdings Manager L.L.C. | 67.2% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 6.8% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.5% of the class | 5%+ stakes | Source |
| January 2, 2026 | Form D, private offering | $100M sold | Form D page | Source |
Selling to them or working with them? See who runs Legence Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on Legence Corp. and the records around it.
Legence Corp. elsewhere on the record
- 5%+ stake filings Aug 2026
- IPO filing Apr 2026
- Company profile and every filing Mar 2026
- Form D filing Mar 2026
- Form D filing Jan 2026
- Who owns it
Companies that share a holder
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Legence Corp.
Get an email when Legence Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Legence Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Legence Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Legence Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-18 | In | Director | 2026-08-18 | 8-K, 2026-08-18 | |
| 2026-08-18 | In | 8-K, 2026-08-18 | |||
| 2026-06-11 | Reported | not named in the filing | 8-K, 2026-06-11 |
Who leads Legence Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Robert Crisci, appointed, effective 2026-08-18 (filed 2026-08-18).
New leaders reset buying decisions — get the Full Report on Legence Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Legence Corp. (free up to 3)
Find people with the same kind of experience as the Director at Legence Corp., with the record behind each one.
Find candidates like Director at Legence Corp.Every change, in the filing's words
Appointed: Robert Crisci, Director, effective 2026-08-18
On August 18, 2026, the Board of Directors (the "Board") of Legence Corp., a Delaware corporation (the "Company"), increased the size of the Board from six to seven directors and appointed Mr. Robert Crisci to the Board as a Class II director to fill the vacancy created by such increase, effective as of August 18, 2026.
Appointed: Robert Crisci
The Board also appointed Mr. Crisci to serve on the Board's Audit Committee and Nomination and Corporate Governance Committee.
- As a Class II director, Mr. Crisci will serve for an initial term that will expire at the annual meeting of shareholders in 2027 or upon his death, resignation, retirement or removal.
- Mr. Crisci, age 51, has extensive public company experience having served as Chief Financial Officer of large public companies where he oversaw financial reporting, audit and internal control processes, among other executive duties.
- He also has significant experience in financial analysis, investor relations and mergers and acquisitions.
- Mr. Crisci served as the Chief Financial Officer for Lineage, Inc. (NASDAQ: LINE) from 2023 until his retirement from that role in November 2025.
- He currently remains at Lineage in an advisory role.
- Mr. Crisci previously served as Chief Financial Officer of Roper Technologies, Inc. (NASDAQ: ROP), an operator of market-leading businesses that design and develop vertical software and technology enabled products, from 2017 until January 2023.
- Mr. Crisci joined Roper Technologies, Inc. in 2013 as Vice President, Finance and Investor Relations and led the company's financial planning and analysis and investor relations activities.
- Prior to joining Roper Technologies, Inc., Mr. Crisci served in various roles across investment banking, consulting and finance.
Reported
The ESPP is designed to allow eligible employees of the Company and certain designated subsidiaries of the Company to purchase shares of the Company's Class A common stock, par value $0.01 per share ("Class A Common Stock"), at a discount to the market price, subject to the requirements of Section 423 of the U.S. Internal Revenue Code of 1986, as amended, and the terms of the ESPP.
- Legence Corp. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 11, 2026.
- At the Annual Meeting, the Company's stockholders approved the Legence Corp. 2026 Employee Stock Purchase Plan (the "ESPP"), which had been previously approved by the Company's Board of Directors, subject to stockholder approval.
- Up to 1,580,053 shares of Class A Common Stock are authorized for issuance pursuant to the ESPP, which number is subject to adjustment for certain corporate and recapitalization events as described in the ESPP.
- A further description of the ESPP is set forth in Proposal 4 of the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the "SEC") on April 29, 2026 (the "Proxy Statement").
Legence Corp.'s funding history
Tools for this story
Each opens in a new tab, filled in for Legence Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.